Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $6.60.

A number of equities research analysts recently commented on CNTX shares. Piper Sandler raised their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Guggenheim reissued a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research note on Tuesday, March 24th. JonesTrading began coverage on Context Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, January 21st. Finally, Lifesci Capital raised Context Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd.

Context Therapeutics Stock Performance

Shares of CNTX opened at $2.65 on Friday. The stock has a market capitalization of $243.48 million, a P/E ratio of -6.97 and a beta of 1.82. Context Therapeutics has a 1 year low of $0.49 and a 1 year high of $3.62. The company’s fifty day moving average is $2.54 and its two-hundred day moving average is $1.67.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Monday, March 23rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sell-side analysts predict that Context Therapeutics will post -0.51 EPS for the current year.

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CNTX. Virtu Financial LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at about $43,000. Quadrature Capital Ltd purchased a new position in Context Therapeutics in the fourth quarter valued at about $68,000. Clear Harbor Asset Management LLC lifted its position in shares of Context Therapeutics by 60.5% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after acquiring an additional 35,000 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics during the 3rd quarter valued at approximately $100,000. Finally, XTX Topco Ltd boosted its stake in shares of Context Therapeutics by 858.8% during the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after acquiring an additional 91,008 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.